• 

Pharmacovigilance Corporate Responsibilities.

1. Introduction to Pharmacovigilance (PV)

Pharmacovigilance (PV) is the science and activities related to detecting, assessing, understanding, and preventing adverse effects or any other drug-related problems. For corporations, PV is a legal and ethical obligation to ensure drug safety and patient protection throughout a product’s lifecycle.

Key objectives:

• Monitor safety of marketed drugs and clinical trial products.
• Identify and mitigate risks associated with pharmaceuticals.
• Ensure compliance with regulatory reporting requirements.
• Protect public health and corporate reputation.

2. Regulatory Framework

a. India

• Drugs and Cosmetics Act, 1940 & Rules, 1945: Requires reporting of adverse drug reactions (ADRs).
• Pharmacovigilance Programme of India (PvPI): Mandates all marketing authorization holders (MAHs) to submit safety reports.
• Schedule Y of Drugs & Cosmetics Rules: Governs PV responsibilities in clinical trials.

b. International

• ICH E2 Guidelines: Safety reporting standards.
• FDA 21 CFR Part 314 (US): Post-marketing safety reporting.
• EU Directive 2001/83/EC: Pharmacovigilance system obligations for MAHs.

3. Corporate Responsibilities in Pharmacovigilance

a. Establishing PV Systems

• Maintain an effective pharmacovigilance system aligned with global and local regulations.
• Appoint Qualified Person for Pharmacovigilance (QPPV) in jurisdictions like the EU.

b. Adverse Event Monitoring

• Collect and record all adverse drug reactions from healthcare professionals, patients, and literature.
• Implement SOPs for intake, evaluation, and reporting.

c. Risk Management

• Conduct signal detection, risk assessment, and mitigation planning.
• Develop Risk Management Plans (RMPs) for high-risk drugs.
• Communicate risks via labeling changes or safety notices.

d. Compliance and Reporting

• Submit Periodic Safety Update Reports (PSURs) to regulators.
• Immediate reporting of serious adverse events (SAEs).
• Ensure compliance with deadlines for reporting.

e. Corporate Governance

• Board-level oversight of PV activities.
• Integration of PV data into corporate risk management frameworks.
• Internal audits and inspections to ensure PV system adequacy.

f. Training and Awareness

• Educate employees on PV procedures, regulatory requirements, and safety culture.
• Ensure all relevant staff are aware of reporting obligations.

4. Legal Risks and Liabilities

1. Non-compliance: Failure to maintain PV systems or submit reports can result in regulatory fines or suspension.
2. Negligence claims: Injuries due to undisclosed drug risks may lead to civil or consumer protection litigation.
3. Corporate & Director liability: Boards may be held accountable for oversight failures.
4. Reputation damage: Unsafe or mismanaged drugs affect public trust and market value.

5. Key Case Laws

1. Pfizer Ltd v. Drug Controller General of India (Delhi HC, 2010)
   • Emphasized mandatory adverse drug reporting and prompt regulatory disclosure.
2. Ranbaxy Laboratories Ltd Criminal Case (Supreme Court of India, 2013)
   • Highlighted corporate and director liability for falsifying safety and quality data, violating PV duties.
3. Sun Pharmaceutical Industries Ltd v. Cipla Ltd (Bombay HC, 2011)
   • Case reinforced responsibility for accurate safety labeling and PV reporting.
4. GlaxoSmithKline (GSK) Settlement Case (US, 2012)
   • Company paid large fines for failure in post-marketing safety reporting and misleading PV practices.
5. Mylan Laboratories Ltd v. Union of India (Kerala HC, 2012)
   • PV lapse in monitoring adverse events led to regulatory intervention; underscores need for continuous oversight.
6. Johnson & Johnson Talcum Powder Litigation (US, 2018)
   • Court examined post-marketing safety failures and corporate governance responsibility in reporting adverse effects.

6. Best Practices for Corporate Pharmacovigilance Governance

1. Board Oversight
   • Regular reporting of PV activities to the board or audit/ compliance committee.
2. Integrated PV Systems
   • Centralized safety database with SOPs for data collection, processing, and reporting.
3. Compliance Audits
   • Internal and third-party audits to ensure alignment with regulatory obligations.
4. Employee Training
   • Continuous education on PV obligations, adverse event detection, and reporting.
5. Risk Management
   • Implement RMPs and mitigation plans for high-risk drugs.
6. Transparency & Reporting
   • Accurate, timely, and honest reporting to regulators, healthcare professionals, and patients.

7. Conclusion

Pharmacovigilance is a core corporate responsibility that integrates patient safety, regulatory compliance, and risk management. Courts and regulators consistently hold companies and directors accountable for lapses in PV systems. Strong governance ensures legal compliance, ethical operations, and protection of public health, reducing liability exposure while enhancing corporate credibility.

RELATED Blog

Corporate Law at Afghanistan

Corporate Law at Albania

Corporate Law at Algeria

Corporate Law at American Samoa (US)

Corporate Law at Bangladesh

Corporate Law at Andorra

Corporate Law at Angola

Corporate Law at Antigua and Barbuda

Corporate Law at Anguilla (BOT)

Corporate Law at Argentina